Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug called vistusertib and weekly paclitaxel chemotherapy for ovarian cancer that has come back. It is for women who have
- Ovarian cancer
- Primary peritoneal cancer
- Fallopian tube cancer
These cancers are treated in a similar way. When we use the term ovarian cancer in this summary, we are referring to all 3. This trial is supported by Cancer Research UK
More about this trial
Doctors usually treat ovarian cancer with surgery followed by chemotherapy. The chemotherapy often includes a platinum drug such as carboplatin. If your cancer gets worse within 6 months of having this treatment, it is called platinum resistant. You may then have treatment with a taxane chemotherapy drug called paclitaxel. But sometimes the cancer starts to grow again. So researchers are looking at ways to delay this.
In this trial, they are looking at vistusertib. It is a type of biological therapy. It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
Doctors know from research that having paclitaxel and vistusertib together may control the cancer for longer. But they want to find out more. In this trial, everyone has paclitaxel and some people have vistusertib.
The aims of the trial are to:
- Find out if adding vistusertib to weekly paclitaxel is a useful treatment for ovarian cancer
- Learn more about the side effects
- Find out how it affects quality of life
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
University of Glasgow
NHS Greater Glasgow and Clyde